What Neurocode does

Neurocode is a CAP-accredited and CLIA-licensed clinical neurodiagnostic laboratory headquartered in Bellingham, Washington, specializing exclusively in diagnostic testing for neurological and neuroimmunological disorders. The company operates a portfolio of more than 30 tests across two principal categories: blood-based and CSF biomarkers for Alzheimer's and other neurodegenerative diseases (including p-Tau 217 via the ALZpath Dx assay on Quanterix's Simoa platform, GFAP, NfL, and Aβ42/40), and cell-based and radioimmunoprecipitation assays for neuroimmunological conditions such as myasthenia gravis, NMOSD, MOGAD, CIDP, and LEMS (including AChR, MuSK, LRP4, AQP4, and MOG antibody tests). Neurocode holds an exclusive North American license from Oxford University for the live cell-based assay for AChR antibodies — the only such test in the U.S. — and its p-Tau 217 assay achieved AUC=0.932 in identifying amyloid-PET positive patients, with results published in JAMA Neurology in February 2024.

The company generates revenue on a per-test, pay-as-you-go basis, with all tests requiring a requisition signed by a licensed healthcare provider. Billing is routed to insurance carriers, third-party payors, or patients; pricing is not publicly disclosed, and sample collection kits are provided free of charge. Go-to-market combines enterprise field sales to neurologists and clinicians with direct-to-consumer patient enablement, supported by a national phlebotomy partnership (My One Medical Source) providing 1,500+ blood draw locations across all 50 U.S. states. Neurocode also serves clinical trials and research customers with a customized offering. The company was founded in 2017 (per legal and timeline records) and operates with a small team of PhD scientists, medical laboratory scientists, pathologists, and clinical chemistry specialists. CEO Roopa Reddy leads the firm. Neurocode is privately held, with no disclosed institutional funding, acquisitions, or parent company affiliation.

Name

Neurocode

Legal name

Neurocode USA Inc.

Website

https://neurocode.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Neurocode is a CAP-accredited, CLIA-licensed clinical neurodiagnostic laboratory in Bellingham, WA, offering 30+ diagnostic tests for Alzheimer's, myasthenia gravis, and other neurological disorders to neurologists, clinicians, and clinical trial sponsors.

Ownership category

akta.pro rank

Product category

Neurological Clinical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

akta.pro secondary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Neurodiagnostic biomarker testing
• Alzheimer's disease diagnostics
• Neuroimmunology autoantibody testing
• Clinical laboratory diagnostics
• Myasthenia gravis testing

Headquarters

HQ city

Bellingham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Laboratory Diagnostic Testing Services: Neurocode operates as a CAP/CLIA-certified clinical laboratory providing diagnostic tests for neurological disorders. Healthcare providers order tests, and Neurocode processes samples (blood, CSF) and delivers results via a secure web portal. Revenue is generated per test, with sample collection kits provided free of charge. Tests include Alzheimer's biomarkers (p-Tau 217, GFAP, NfL, Aβ42/40), and neuroimmunology assays (AChR, MuSK, LRP4, AQP4, MOG antibodies). All tests must be ordered by a licensed healthcare provider.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Neurocode is a CAP/CLIA-certified clinical laboratory that runs specialty diagnostic tests for neurological and neuroimmunological disorders. Its portfolio includes blood- and CSF-based biomarkers for Alzheimer's and neurodegenerative disease (p-Tau 217, GFAP, NfL, Aβ42/40 ratio) and cell-based and radioimmunoprecipitation assays for autoantibody-mediated disorders such as myasthenia gravis, NMOSD, MOGAD, and CIDP. Tests are performed on patient samples (blood or CSF) collected through free collection kits and a national phlebotomy partner network, with results delivered to clinicians via a secure web portal.

Product overview

Neurocode Laboratory is a specialized clinical neurodiagnostic laboratory offering a portfolio of diagnostic tests for neurological disorders. The company provides two main categories of testing: neurodegenerative disease biomarkers including blood-based Alzheimer's tests (p-Tau 217, GFAP, NfL, Aβ42/40) and neuroimmunology tests for myasthenia gravis and related conditions (AChR CBA, AChR RIPA, MuSK RIPA, LRP4 CBA, AQP4 CBA, MOG CBA). Tests use various methodologies including single-molecule array (Simoa), cell-based assays (CBA), radioimmunoprecipitation (RIPA), and chemiluminescence assay (CLEIA). The company operates CAP-accredited and CLIA-certified facilities.

Differentiator

Problem solved

Functional benefit

Brands

• ALZpath Dx: Plasma Phosphorylated Tau 217 (p-Tau 217) test - a breakthrough blood test for Alzheimer's disease diagnosis
• AChR CBA

Products and services

• ALZpath Dx: Plasma Phosphorylated Tau 217 (p-Tau 217) Blood-based biomarker test that measures phosphorylated tau 217 levels using Simoa single-molecule array technology to assist in diagnosis of Alzheimer's disease amyloid pathology; reported AUC=0.932 for identifying amyloid-PET positive patients and validated in JAMA Neurology.
• Acetylcholine Receptor Antibodies by Live Cell-Based Assay (AChR CBA) Live cell-based assay that detects acetylcholine receptor antibodies with maximum sensitivity and specificity to assist in diagnosis of autoimmune myasthenia gravis, including in double-seronegative cases; licensed from Oxford University for exclusive use across North America.
• Acetylcholine Receptor Antibodies by Radioimmunoprecipitation (AChR RIPA) Radioimmunoprecipitation assay that detects acetylcholine receptor antibodies to assist in diagnosis of autoimmune myasthenia gravis.
• Muscle Specific Kinase Antibodies by Radioimmunoprecipitation (MuSK RIPA) Radioimmunoprecipitation assay that detects MuSK antibodies to assist in diagnosis of autoimmune myasthenia gravis.
• Low-Density Lipoprotein Receptor-Related Protein 4 Antibodies by Fixed Cell-Based Assay (LRP4 CBA) Fixed cell-based assay that detects LRP4 antibodies to assist in diagnosis of autoimmune myasthenia gravis.
• Aquaporin-4 Antibodies by Live Cell-Based Assay (AQP4 CBA) Live cell-based assay that detects aquaporin-4 antibodies to assist in diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and to distinguish it from multiple sclerosis.
• Myelin Oligodendrocyte Antibodies by Live Cell-Based Assay (MOG CBA) Live cell-based assay that detects MOG antibodies to assist in diagnosis of myelin oligodendrocyte glycoprotein antibody disease (MOGAD).
• Plasma Glial Fibrillary Acidic Protein (GFAP) Blood-based chemiluminescence assay that measures plasma GFAP levels to assist in assessment of neurological disorders.
• Plasma Neurofilament Light Chain (NfL) Chemiluminescent enzyme immunoassay that quantifies neurofilament light chain in plasma as a nonspecific biomarker of axonal degeneration associated with neurological disorders including Alzheimer's, ALS, MS, FTD, and TBI.
• CSF Amyloid-Beta 42/40 Ratio (Aβ42/40) Cerebrospinal fluid test that measures the amyloid-beta 42/40 ratio as an in vitro diagnostic to assess underlying Alzheimer's disease-associated pathology in conjunction with clinical assessment.

Quantifiable outcome

• ALZpath p-Tau 217 assay achieved AUC=0.932 in identifying amyloid-PET positive patients
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Oxford UniversitycoreTechnology or IntegrationNeurocode holds an exclusive license from Oxford University for the live cell-based assay (CBA) for acetylcholine receptor (AChR) antibodies across all of North America. This is the only live CBA for AChR antibodies in the U.S. and provides maximum sensitivity for myasthenia gravis diagnosis — more sensitive than standard RIPA or ELISA methods.
• ALZpathcoreTechnology or IntegrationNeurocode offers the ALZpath Dx Plasma Phosphorylated Tau 217 (p-Tau 217) test, a groundbreaking blood test for Alzheimer's diagnosis. ALZpath is the developer of the p-Tau 217 assay, and Neurocode performs the test using in-house Simoa technology.
• FujirebiominorStrategic or Co-development PartnerNeurocode conducted a head-to-head comparison study between their ALZpath p-Tau217 assay and Fujirebio's p-Tau217 assay, published as a preprint in Alzheimer's & Dementia (2024). This comparative study validates Neurocode's assay performance against a competitor.
• My One Medical SourcecoreChannel Partner/ Reseller/ DistributorNational phlebotomy partner with over 1,500 convenient locations across all 50 U.S. states. Patients are referred to My One Medical Source for blood draw appointments. Mobile phlebotomy is available for an additional charge. Neurocode includes this partner network as a core component of its patient logistics.
• Simoa (Quanterix)coreTechnology or IntegrationNeurocode's ALZpath p-Tau 217 assay is powered by Simoa (Single Molecule Array) technology from Quanterix. This platform enables ultra-sensitive detection of p-Tau 217 protein at the single-molecule level, achieving AUC=0.932 accuracy.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Siemens Healthineers: Siemens Healthineers offers the ADVIA Centaur and Atellica immunoassay platforms that are increasingly being developed for neurodegenerative biomarkers including p-Tau 217. As a major IVD platform provider, Siemens represents a long-term competitive threat if it launches comparable blood-based Alzheimer's assays at scale.
• Quest Diagnostics: Quest Diagnostics is the largest U.S. clinical reference lab and parent of Athena Diagnostics. Quest competes via national logistics, payor relationships, and routine physician office relationships that are difficult for specialty labs to penetrate. Quest is actively adding Alzheimer's and neuroimmunology blood tests to its menu.
• Mayo Clinic Laboratories: Mayo Clinic Laboratories is a major academic reference lab offering extensive neurology and neuroimmunology testing, including cell-based assays and Alzheimer's biomarkers. Mayo has unrivaled brand authority with U.S. neurologists and serves as the default send-out lab for many academic medical centers.
• ARUP Laboratories: ARUP is a national reference laboratory owned by the University of Utah offering extensive neurology, autoimmune, and neuroimmunology testing. ARUP competes with Neurocode in autoantibody testing and serves as a primary reference lab for many U.S. health systems.
• LabCorp: LabCorp is one of the two largest U.S. clinical reference labs, offering a broad neurology and neuroimmunology menu including MNG Laboratories (acquired 2019). LabCorp competes through scale, payor contracts, and sales force reach that Neurocode cannot match directly.

Direct peers

• C2N Diagnostics: C2N Diagnostics is the most direct competitor in blood-based Alzheimer's biomarkers with its PrecivityAD test (Aβ42/40 ratio). Both companies are pursuing the same market: replacing PET scans and CSF testing with blood-based assays for amyloid pathology detection. C2N has raised substantial funding and is scaling nationally.
• Euroimmun (PerkinElmer): Euroimmun, owned by PerkinElmer, is a leading autoimmune diagnostics company offering cell-based assays for neuroimmunology indications including AChR, MuSK, and AQP4 antibodies. Euroimmun and Neurocode directly compete in neuroimmunology autoantibody testing globally.
• Athena Diagnostics (Quest Diagnostics): Athena Diagnostics is a Quest subsidiary focused specifically on neurodiagnostic testing, including myasthenia gravis, autoimmune encephalitis, and paraneoplastic panels — directly overlapping Neurocode's neuroimmunology menu. Athena has a much larger sales force and payor footprint but historically lower sensitivity on cell-based assays.
• Fujirebio: Fujirebio is the most direct head-to-head competitor for Alzheimer's p-Tau 217 testing via its Lumipulse G pTau 217 assay. Neurocode published a direct comparison study vs. Fujirebio's assay in Alzheimer's & Dementia (2024). Fujirebio has FDA breakthrough designation and a major global installed base of chemiluminescence immunoassay instruments.

Others

• Quanterix: Quanterix develops the Simoa single-molecule array platform that powers Neurocode's p-Tau 217 assay. Quanterix is both a critical technology partner and a potential competitor through its AccuDx direct testing service. Vertical integration risk: if Quanterix brings biomarker testing in-house, Neurocode becomes a customer rather than a service provider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neurocode-labs-inc.

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurocode